<DOC>
	<DOCNO>NCT01076205</DOCNO>
	<brief_summary>The primary objective study explore therapeutic success , measure improvement follow variable : - The number miss working day The secondary objective document therapeutic success follow variable : - The number physician visit - The number duration hospitalization - The number day impairment non-occupational activity - The duration morning stiffness , pain , exhaustion/fatigue</brief_summary>
	<brief_title>Safety Effect Quality Life/Work Productivity Humira Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>The primary objective study explore therapeutic success , measure improvement target variable : - The number miss work day - The self-assessed work ability ( modify WAI ) - The severity clinical symptom ( number tender swollen joint , C-reactive Protein Erythrocyte Sedimentation Rate , respectively ; Disease Activity Score 28 ) - The severity functional impairment ( Health Assessment Questionnaire ) - The health-related quality life . All patient disease characteristic document baseline evaluate additional impact target variable ( therapeutic success ) . Particularly impact previous biologic therapy clinical target variable evaluate . The secondary objective document therapeutic success follow variable : - The number physician visit - The number duration hospitalization - The number day impairment non-occupational activity - The duration morning stiffness , pain , exhaustion/fatigue . - The reduction number dose concomitant medication - Patient assessment adalimumab therapy compare previous therapy . Target parameter safety evaluation adalimumab : - The evaluation safety tolerability documentation analysis serious adverse event ( SAEs ) adverse event ( AEs ) - Evaluation safety tolerability subgroup patient common frequent concomitant disease , especially diabetes type II , cardiovascular , liver , renal insufficiency , relate concomitant medication .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Moderate severe active rheumatoid arthritis adult insufficient response diseasemodifying antirheumatic drug Inclusive methotrexate Moderate severe active rheumatoid arthritis adult treat methotrexate ; In case incompatibility methotrexate , Humira use monotherapy . Hypersensitivity drug one ingredient Active tuberculosis severe infection ( e.g . sepsis opportunistic infection ) Moderate severe cardiac insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Work Productivity</keyword>
	<keyword>Long-term Observation</keyword>
	<keyword>Humira</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>